P2RX7 and myeloid sarcoma: However, monocytes from MS patients undergoing treatment with glatiramer acetate—which acts displacing myelin basic protein from the binding site on MHC-II molecules, preventing the activation of myelin-specific T cells—exhibit reduced P2X7 receptor and interleukin (IL)-1β expression, indicating that this treatment may act by decreasing P2X7 receptor pro-inflammatory effects (Caragnano et al., 2012).